Prevalence and treatment of anemia in chronic kidney disease patients based on regional medical big data.
10.3760/cma.j.cn112338-20221201-01028
- Author:
Yang Fan CHAI
1
;
Hong Bo LIN
2
;
Guo Hui DING
3
;
Jin Wei WANG
4
;
Huai Yu WANG
5
;
Su Yuan PENG
5
;
Bi Xia GAO
4
;
Xin Wei DENG
4
;
Gui Lan KONG
1
;
Bei Yan BAO
6
;
Lu Xia ZHANG
7
Author Information
1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China National Institute of Health Data Science, Peking University, Beijing 100191,China.
2. Yinzhou District Center for Disease Control and Prevention of Ningbo, Ningbo 315199, China.
3. School of Computer Science, Shenyang Aerospace University, Shenyang 110136, China.
4. Department of Nephrology, Peking University First Hospital, Beijing 100034, China.
5. National Institute of Health Data Science, Peking University, Beijing 100191,China.
6. Ningbo Urology and Nephrology Hospital, Ningbo 315100, China.
7. National Institute of Health Data Science, Peking University, Beijing 100191,China Department of Nephrology, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Journal Article
- From:
Chinese Journal of Epidemiology
2023;44(7):1046-1053
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the prevalence, risk factors and treatment of anemia in patients with chronic kidney disease (CKD). Methods: A descriptive method was used to analyze the prevalence and treatment of anemia in CKD patients based on regional health data in Yinzhou District of Ningbo during 2012-2018. The multivariate logistic regression analysis was used to identify independent influence factors of anemia in the CKD patients. Results: In 52 619 CKD patients, 15 639 suffered from by anemia (29.72%), in whom 5 461 were men (26.41%) and 10 178 were women (31.87%), and anemia prevalence was higher in women than in men, the difference was significant (P<0.001). The prevalence of anemia increased with stage of CKD (24.77% in stage 1 vs. 69.42% in stage 5, trend χ2 test P<0.001). Multivariate logistic regression analysis revealed that being women (aOR=1.57, 95%CI: 1.50-1.63), CKD stage (stage 2: aOR=1.10, 95%CI: 1.04-1.16;stage 3: aOR=2.28,95%CI: 2.12-2.44;stage 4: aOR=4.49,95%CI :3.79-5.32;stage 5: aOR=6.31,95%CI: 4.74-8.39), age (18-30 years old: aOR=2.40,95%CI: 2.24-2.57, 61-75 years old: aOR=1.35,95%CI:1.28-1.42, ≥76 years old: aOR=2.37,95%CI:2.20-2.55), BMI (<18.5 kg/m2:aOR=1.29,95%CI: 1.18-1.41;23.0-24.9 kg/m2:aOR=0.79,95%CI: 0.75-0.83;≥25.0 kg/m2:aOR=0.70,95%CI: 0.66-0.74), abdominal obesity (aOR=0.91, 95%CI: 0.86-0.96), chronic obstructive pulmonary disease (aOR=1.15, 95%CI: 1.09-1.22), cancer (aOR=3.03, 95%CI: 2.84-3.23), heart failure (aOR=1.44, 95%CI: 1.35-1.54) and myocardial infarction (aOR=1.54, 95%CI:1.16-2.04) were independent risk factors of anemia in CKD patients. Among stage 3-5 CKD patients with anemia, 12.03% received iron therapy, and 4.78% received treatment with erythropoiesis-stimulating agent (ESA) within 12 months after anemia was diagnosed. Conclusions: The prevalence of anemia in CKD patients was high in Yinzhou. However, the treatment rate of iron therapy and ESA were low. More attention should be paid to the anemia management and treatment in CKD patients.
